FDA advisers endorse Eli Lilly’s early-stage Alzheimer’s drug donanemab
By Jen Christensen, CNN (CNN) — On Monday, a panel of independent advisers to the US Food and Drug Administration voted to endorse Eli Lilly’s drug donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease, agreeing that it was safe and effective. One in three older Americans dies with Alzheimer’s
Continue Reading